Novartis shares: remibrutinib Phase III win; YTB323 halt
Novartis reported mixed clinical outcomes: remibrutinib met Phase III relapsing MS endpoints for a planned MSTORONTO2026 presentation. The firm paused YTB323 after patient deaths and saw a failed cardiovascular Phase III.